tbuckley/cabot-search huggingface dataset:
873P Early efficacy prediction of nasopharyngeal carcinoma based on 3D-ADC acquired during radiotherapy: A phase II prospective study
Authors: M. Feng, L. Yan, X. Du, H. Wang, J. Ren, M. Wang, Q. Yin, X. Lai, L. Li, M. Lan, S. Lu, Y. Huang, F. Li, X. Xu, W. Wang, J. Lang
Journal: Annals of Oncology (2021)
Laminar Flow on Endothelial Cells Suppresses eNOS O-GlcNAcylation to Promote eNOS Activity
Authors: Sarah E. Basehore, Samantha Bohlman, Callie Weber, Swathi Swaminathan, Yuji Zhang, Cholsoon Jang, Zoltan Arany, Alisa Morss Clyne
Journal: Circulation Research (2021)

Rationale: In diabetic animals as well as high glucose cell culture conditions, eNOS (endothelial NO synthase) is heavily O-linked-N-acetylglucosaminylated (O-GlcNAcylated), which inhibits its phosphorylation and NO production. It is unknown, however, whether varied blood flow conditions, which affect eNOS phosphorylation, modulate eNOS activity via O-GlcNAcylation-dependent mechanisms. Objective: The goal of this study was to test if steady laminar flow, but not oscillating disturbed flow, decreases eNOS O-GlcNAcylation, thereby elevating eNOS phosphorylation and NO production. Methods and Results: Human umbilical vein endothelial cells were exposed to either laminar flow (20 dynes/cm 2 shear stress) or oscillating disturbed flow (4±6 dynes/cm 2 shear stress) for 24 hours in a cone-and-plate device. eNOS O-GlcNAcylation was almost completely abolished in cells exposed to steady laminar but not oscillating disturbed flow. Interestingly, there was no change in protein level or activity of key O-GlcNAcylation enzymes (OGT [O-GlcNAc transferase], OGA [O-GlcNAcase], or GFAT [glucosamine-fructose-6-phosphate aminotransferase]). Instead, metabolomics data suggest that steady laminar flow decreases glycolysis and hexosamine biosynthetic pathway activity, thereby reducing UDP-GlcNAc (uridine diphosphate N-acetylglucosamine) pool size and consequent O-GlcNAcylation. Inhibition of glycolysis via 2-deoxy-2-glucose in cells exposed to disturbed flow efficiently decreased eNOS O-GlcNAcylation, thereby increasing eNOS phosphorylation and NO production. Finally, we detected significantly higher O-GlcNAcylated proteins in endothelium of the inner aortic arch in mice, suggesting that disturbed flow increases protein O-GlcNAcylation in vivo. Conclusions: Our data demonstrate that steady laminar but not oscillating disturbed flow decreases eNOS O-GlcNAcylation by limiting glycolysis and UDP-GlcNAc substrate availability, thus enhancing eNOS phosphorylation and NO production. This research shows for the first time that O-GlcNAcylation is regulated by mechanical stimuli, relates flow-induced glycolytic reductions to macrovascular disease, and highlights targeting hexosamine biosynthetic pathway metabolic enzymes in endothelial cells as a novel therapeutic strategy to restore eNOS activity and prevent endothelial cell dysfunction in cardiovascular disease.
1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC)
Authors: M. Aldea, C. Parisi, A. Mogenet, L. Cerbone, D. Vasseur, P. Lavaud, C. Naltet, P. Abdayem, A. Gazzah, A. Botticella, A. Levy, C. Le Pechoux, J. Le Pavec, O. Mercier, E. Rouleau, B. Besse, J-C. Soria, F. Barlesi, P. Pradere, D. Planchard
Journal: Annals of Oncology (2021)
610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results
Authors: P. Monk, J. Zhang, D. Costin, D.P. Petrylak, S.T. Tagawa, L.I. Karsh, X. Zhu, M. Linch, R. Jones, P. Borderies, V. O'Neill, R.R. Aggarwal
Journal: Annals of Oncology (2021)
Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice
Authors: Rachael C. Adams, Dylan Carter-Cusack, Samreen N. Shaikh, Genesis T. Llanes, Rebecca L. Johnston, Gregory Quaife-Ryan, Glen Boyle, Lambros T. Koufariotis, Andreas Möller, Bruce R. Blazar, Jana Vukovic, Kelli P. A. MacDonald
Journal: Blood (2021)

Graft-versus-host disease (GVHD) remains the leading cause of nonrelapse mortality after allogeneic stem cell transplantation for hematological malignancies. Manifestations of GVHD in the central nervous system (CNS) present as neurocognitive dysfunction in up to 60% of patients; however, the mechanisms driving chronic GVHD (cGVHD) in the CNS are yet to be elucidated. Our studies of murine cGVHD revealed behavioral deficits associated with broad neuroinflammation and persistent Ifng upregulation. By flow cytometry, we observed a proportional shift in the donor-derived T-cell population in the cGVHD brain from early CD8 dominance to later CD4 sequestration. RNA sequencing of the hippocampus identified perturbations to structural and functional synapse-related gene expression, together with the upregulation of genes associated with interferon-γ responses and antigen presentation. Neuroinflammation in the cortex of mice and humans during acute GVHD was recently shown to be mediated by resident microglia-derived tumor necrosis factor. In contrast, infiltration of proinflammatory major histocompatibility complex (MHC) class II+ donor bone marrow (BM)-derived macrophages (BMDMs) was identified as a distinguishing feature of CNS cGVHD. Donor BMDMs, which composed up to 50% of the CNS myeloid population, exhibited a transcriptional signature distinct from resident microglia. Recipients of MHC class II knockout BM grafts exhibited attenuated neuroinflammation and behavior comparable to controls, suggestive of a critical role of donor BMDM MHC class II expression in CNS cGVHD. Our identification of disease mediators distinct from those in the acute phase indicates the necessity to pursue alternative therapeutic targets for late-stage neurological manifestations.
1438TiP INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
Authors: N. Pavlakis, K. Shitara, K. Sjoquist, A.J. Martin, A. Jaworski, S. Yip, D-Y. Oh, M. Moehler, L-T. Chen, T. Bekaii-Saab, J. Simes, D. Goldstein
Journal: Annals of Oncology (2021)
1756TiP Dabrafenib and trametinib combination as a neoadjuvant strategy in BRAF-positive anaplastic thyroid cancer (ANAPLAST-NEO)
Authors: Y.V. Mikheeva, A.A. Tikhonov, I. Sleptsov, R. Chernikov, A. Turdubaeva
Journal: Annals of Oncology (2021)
740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
Authors: K. Lindemann, E. Škof, N. Colombo, A. González-Martín, R. Davidson, C. Blakeley, J. Bennett, A. Barnicle, A. Poveda
Journal: Annals of Oncology (2021)
CN10 Congruence between actual and preferred place of death by patients with oncological disease in palliative care and their caregivers in a primary care district of Cadiz
Authors: C. Sancho-Salvatierra, J.M. Martinez-Nieto, A. Delgado-Romero, M.J. Gomez-Plana, M.D.M. Leon-Grima, L. Arias-Velarde, P. Ruiz-Cayuso, C. Tello-Meneses, M.A. Ramirez-Castillo, J. Fernandez-Rodriguez, F. Moreno-Castro, J.A. Rubio-Muñoz, F.J. Perez-Cabezas, L. Diaz-Martinez, M.I. Barberan-Montiano, B. Ardaiz-Flamarique, J.M. Caparros-Garcia, A.D. Romero
Journal: Annals of Oncology (2021)
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Authors: Robin Reschke, Jovian Yu, Blake A Flood, Emily F Higgs, Ken Hatogai, Thomas F Gajewski
Journal: Journal for ImmunoTherapy of Cancer (2021)

A T cell-inflamed tumor microenvironment is characterized by the accumulation and local activation of CD8+ T cells and Bat3-lineage dendritic cells, which together are associated with clinical response to anti-programmed cell death protein 1 (anti-PD-1)-based immunotherapy. Preclinical models have demonstrated a crucial role for the chemokine CXCL10 in the recruitment of effector CD8+ T cells into the tumor site, and a chemokine gene signature is also seen in T cell-inflamed tumors from patients. However, the cellular source of CXCL10 in human solid tumors is not known. To identify the cellular source of CXCL10 we analyzed 22 pretreatment biopsy samples of melanoma metastases from patients who subsequently underwent checkpoint blockade immunotherapy. We stained for CD45+ and Sox10+ cells with multiparameter immunofluorescence staining, and RNA in situ hybridization technology was used in concert to identify CXCL10 transcripts. The results were correlated with the expression levels of CXCL10 transcripts from bulk RNA sequencing and the best overall response to immune checkpoint inhibition (anti-PD-1 alone or with anti-CTLA-4) in the same patients. We identified CD45+ cells as the major cellular source for CXCL10 in human melanoma metastases, with additional CXCL10 production seen by Sox10+ cells. Up to 90% of CD45+ cells and up to 69% of Sox10+ cells produced CXCL10 transcripts. The CXCL10 staining result was consistent with the level of CXCL10 expression determined by bulk RNA sequencing. The percentages of CD45+ CXCL10+ cells and Sox10+ CXCL10+ cells independently predicted response (p<0.001). The average number of transcripts per cell correlated with the CD45+ cell infiltrate (R=0.37). Immune cells and melanoma cells produce CXCL10 in human melanoma metastases. Intratumoral CXCL10 is a positive prognostic factor for response to immunotherapy, and the RNAscope technique is achievable using paraffin tissue. Strategies that support effector T cell recruitment via induction of CXCL10 should be considered as a mechanism-based intervention to expand immunotherapy efficacy.
Circadian disruption and human health
Authors: Anna B. Fishbein, Kristen L. Knutson, Phyllis C. Zee
Journal: Journal of Clinical Investigation (2021)

Circadian disruption is pervasive and can occur at multiple organizational levels, contributing to poor health outcomes at individual and population levels. Evidence points to a bidirectional relationship, in that circadian disruption increases disease severity and many diseases can disrupt circadian rhythms. Importantly, circadian disruption can increase the risk for the expression and development of neurologic, psychiatric, cardiometabolic, and immune disorders. Thus, harnessing the rich findings from preclinical and translational research in circadian biology to enhance health via circadian-based approaches represents a unique opportunity for personalized/precision medicine and overall societal well-being. In this Review, we discuss the implications of circadian disruption for human health using a bench-to-bedside approach. Evidence from preclinical and translational science is applied to a clinical and population-based approach. Given the broad implications of circadian regulation for human health, this Review focuses its discussion on selected examples in neurologic, psychiatric, metabolic, cardiovascular, allergic, and immunologic disorders that highlight the interrelatedness between circadian disruption and human disease and the potential of circadian-based interventions, such as bright light therapy and exogenous melatonin, as well as chronotherapy to improve and/or modify disease outcomes.
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant
Authors: Laura T. Gray, Michal M. Raczy, Priscilla S. Briquez, Tiffany M. Marchell, Aaron T. Alpar, Rachel P. Wallace, Lisa R. Volpatti, Maria Stella Sasso, Shijie Cao, Mindy Nguyen, Aslan Mansurov, Erica Budina, Elyse A. Watkins, Ani Solanki, Nikolaos Mitrousis, Joseph W. Reda, Shann S. Yu, Andrew C. Tremain, Ruyi Wang, Vlad Nicolaescu, Kevin Furlong, Steve Dvorkin, Balaji Manicassamy, Glenn Randall, D. Scott Wilson, Marcin Kwissa, Melody A. Swartz, Jeffrey A. Hubbell
Journal: Biomaterials (2021)

The SARS-CoV-2 virus has caused an unprecedented global crisis, and curtailing its spread requires an effective vaccine which elicits a diverse and robust immune response. We have previously shown that vaccines made of a polymeric glyco-adjuvant conjugated to an antigen were effective in triggering such a response in other disease models and hypothesized that the technology could be adapted to create an effective vaccine against SARS-CoV-2. The core of the vaccine platform is the copolymer p(Man-TLR7), composed of monomers with pendant mannose or a toll-like receptor 7 (TLR7) agonist. Thus, p(Man-TLR7) is designed to target relevant antigen-presenting cells (APCs) via mannose-binding receptors and then activate TLR7 upon endocytosis. The p(Man-TLR7) construct is amenable to conjugation to protein antigens such as the Spike protein of SARS-CoV-2, yielding Spike-p(Man-TLR7). Here, we demonstrate Spike-p(Man-TLR7) vaccination elicits robust antigen-specific cellular and humoral responses in mice. In adult and elderly wild-type mice, vaccination with Spike-p(Man-TLR7) generates high and long-lasting titers of anti-Spike IgGs, with neutralizing titers exceeding levels in convalescent human serum. Interestingly, adsorbing Spike-p(Man-TLR7) to the depot-forming adjuvant alum amplified the broadly neutralizing humoral responses to levels matching those in mice vaccinated with formulations based off of clinically-approved adjuvants. Additionally, we observed an increase in germinal center B cells, antigen-specific antibody secreting cells, activated T follicular helper cells, and polyfunctional Th1-cytokine producing CD4
Improved post-stroke spontaneous recovery by astrocytic extracellular vesicles
Authors: Yessica Heras-Romero, Axayacatl Morales-Guadarrama, Ricardo Santana-Martínez, Isaac Ponce, Ruth Rincón-Heredia, Augusto César Poot-Hernández, Araceli Martínez-Moreno, Esteban Urrieta, Berenice N. Bernal-Vicente, Aura N. Campero-Romero, Perla Moreno-Castilla, Nigel H. Greig, Martha L. Escobar, Luis Concha, Luis B. Tovar-y-Romo
Journal: Molecular Therapy (2021)

Spontaneous recovery after a stroke accounts for a significant part of the neurological recovery in patients. However limited, the spontaneous recovery is mechanistically driven by axonal restorative processes for which several molecular cues have been previously described. We report the acceleration of spontaneous recovery in a preclinical model of ischemia/reperfusion in rats via a single intracerebroventricular administration of extracellular vesicles released from primary cortical astrocytes. We used magnetic resonance imaging and confocal and multiphoton microscopy to correlate the structural remodeling of the corpus callosum and striatocortical circuits with neurological performance during 21 days. We also evaluated the functionality of the corpus callosum by repetitive recordings of compound action potentials to show that the recovery facilitated by astrocytic extracellular vesicles was both anatomical and functional. Our data provide compelling evidence that astrocytes can hasten the basal recovery that naturally occurs post-stroke through the release of cellular mediators contained in extracellular vesicles.
Stress hematopoiesis induces a proliferative advantage in TET2 deficiency
Authors: Vinothkumar Rajan, Keon Collett, Rachel Woodside, Sergey V. Prykhozhij, Michelle Moksa, Annäick Carles, Marcus Wong, Mira Liebman, Martin Hirst, Jason N. Berman
Journal: Leukemia (2021)
P-197 The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO)
Authors: M. Cesca, E. Ruiz-Garcia, R. Weschenfelder, N. D'Agustini, S. Iseas, A. Pereira, C. Mello, R. Riechelmann
Journal: Annals of Oncology (2021)
1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Authors: A. Ribas, J. Chesney, G.V. Long, J.M. Kirkwood, R. Dummer, I. Puzanov, C. Hoeller, T.F. Gajewski, R. Gutzmer, P. Rutkowski, L. Demidov, P. Arenberger, S.J. Shin, P.F. Ferrucci, S.J. Diede, J.R. Anderson, S. Treichel, E. Chan, F.S. Hodi, H.J. Gogas
Journal: Annals of Oncology (2021)
1058P Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Authors: M. Pillai, R.E. Hawkins, Y. Jiang, P.C. Lorigan, F. Thistlethwaite, M. Thomas, N. Kirillova, J.S. Bridgeman, G. Kueberuwa, R.D. Guest, Z.J. Roberts
Journal: Annals of Oncology (2021)
1522MO Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF)
Authors: M. Debaudringhien, J-Y. Blay, A.M. Bimbai, S. Bonvalot, A. Italiano, C. Rousset-Jablonski, N. Corradini, S. Piperno-Neumann, C.M. Chevreau, J.E. Kurtz, C. Guillemet, E. Bompas, O. Collard, S. Salas, A. Le Cesne, D. Orbach, J. Thery, M-C. Le Deley, O. Mir, N. Penel
Journal: Annals of Oncology (2021)
30P Targeting of BCR-ABL gene expression in K562 cells using cell-penetrating peptide nanocomplexes carrying siRNAs
Authors: V. Vysochinskaya, N.A. Knyazev, A. Emelyanov, I. Terterov, V. Klimenko, A.A. Bogdanov, M. Dubina
Journal: Annals of Oncology (2021)
1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
Authors: M. Joerger, Y. Metaxas, K. Zaman, O.A. Michielin, N. Mach, D. Betticher, A.M. Schmitt, N. Cantoni, C.B. Caspar, S. Stettler, R. Malval, M. Pless, C. Britschgi, C. Renner, D. Koeberle, J. Schulz, C. Kopp, S. Hayoz, A. Stathis, R. von Moos
Journal: Annals of Oncology (2021)
Changes in exposure to ambient fine particulate matter after relocating and long term survival in Canada: quasi-experimental study
Authors: Hong Chen, Jay S Kaufman, Toyib Olaniyan, Lauren Pinault, Michael Tjepkema, Li Chen, Aaron van Donkelaar, Randall V Martin, Perry Hystad, Chen Chen, Megan Kirby-McGregor, Li Bai, Richard T Burnett, Tarik Benmarhnia
Journal: BMJ (2021)

To investigate the association between changes in long term residential exposure to ambient fine particulate matter (PM2.5) and premature mortality in Canada.Population based quasi-experimental study.Canada.663 100 respondents to the 1996, 2001, and 2006 Canadian censuses aged 25-89 years who had consistently lived in areas with either high or low PM2.5 levels over five years preceding census day and moved during the ensuing five years.Changes in long term exposure to PM2.5 arising from residential mobility.The primary outcome was deaths from natural causes. Secondary outcomes were deaths from any cardiometabolic cause, any respiratory cause, and any cancer cause. All outcomes were obtained from the national vital statistics database.Using a propensity score matching technique with numerous personal, socioeconomic, health, and environment related covariates, each participant who moved to a different PM2.5 area was matched with up to three participants who moved within the same PM2.5 area. In the matched groups that moved from high to intermediate or low PM2.5 areas, residential mobility was associated with a decline in annual PM2.5 exposure from 10.6 μg/m3 to 7.4 and 5.0 μg/m3, respectively. Conversely, in the matched groups that moved from low to intermediate or high PM2.5 areas, annual PM2.5 increased from 4.6 μg/m3 to 6.7 and 9.2 μg/m3. Five years after moving, individuals who experienced a reduction in exposure to PM2.5 from high to intermediate levels showed a 6.8% (95% confidence interval 1.7% to 11.7%) reduction in mortality (2510 deaths in 56 025 v 4925 deaths in 101 960). A greater decline in mortality occurred among those exposed to a larger reduction in PM2.5. Increased mortality was found with exposure to PM2.5 from low to high levels, and to a lesser degree from low to intermediate levels. Furthermore, the decreases in PM2.5 exposure were most strongly associated with reductions in cardiometabolic deaths, whereas the increases in PM2.5 exposure were mostly related to respiratory deaths. No strong evidence was found for the changes in PM2.5 exposure with cancer related deaths.In Canada, decreases in PM2.5 were associated with lower mortality, whereas increases in PM2.5 were associated with higher mortality. These results were observed at PM2.5 levels considerably lower than many other countries, providing support for continuously improving air quality.
B細胞悪性腫瘍の異種移植マウスモデルにおけるナチュラル制御性T細胞によるin vivoでのヒト CD19標的エフェクターT細胞の阻害
Authors: C Lee James, Hayman Erik, J Pegram Hollie, Santos Elmer, Heller Glenn, Sadelain Michel, Brentjens Renier
Journal: Cancer Research (2011)
118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
Authors: L. Del Mastro, M. Mansutti, G. Bisagni, R. Ponzone, A. Durando, L. Amaducci, F. Cognetti, A. Frassoldati, A. Michelotti, S. Mura, Y. Urracci, G. Sanna, S. Gori, S. De Placido, O. Garrone, C. Barone, C. Bighin, F. Poggio, M. Lambertini, P. Bruzzi
Journal: Annals of Oncology (2021)
Expert Performance in Visual Differentiation of Bacterial and Fungal Keratitis
Authors: Travis K. Redd, N. Venkatesh Prajna, Muthiah Srinivasan, Prajna Lalitha, Tiru Krishnan, Revathi Rajaraman, Anitha Venugopal, Brandon Lujan, Nisha Acharya, Gerami D. Seitzman, Jennifer Rose-Nussbaumer, Thomas M. Lietman, J. Peter Campbell, Jeremy D. Keenan, Diana Alvarez-Melloni, Menen Ayalew, Ashwin Balasubramanian, Elsie Chan, Matilda Chan, Meenu Chaudhary, Thomas Chia, James Chodosh, Y.Y. Choong, Joseph Christenbury, Josephine Christy, John Clements, John Dart, Mohammad Dastjerdi, Matthew Denny, Sathish Devarajan, Mohamed Elghobaier, Chris Estopinal, Preethika Gandhi, Nikhil Gokhale, Colleen Halfpenny, Rossen Hazarbassanov, Natalie Hernandez, Anna Hovakimyan, David Hwang, Frank Hwang, Tomas Jaeschke, Vishal Jhanji, Faris Karas, Divya Karthik, Camila Kase, Lakshmi Kattana, Tyson Kim, Aaleya Koreishi, David Liang, Christine Martinez, Rafael Martinez-Costa, Stephen McLeod, Jodhbir S. Mehta, Michael Mimouni, Adam Moss, Afshan Nanji, Nathan Nataneli, Vasudha Panday, Sayali Pradhan, Ying Qian, Naveen Rao, Julie Schallhorn, Ruti Sella, Suvitha Selvaraj, David Spokes, Neha Shaik, Nakul Shekhawat, Alan Sugar, Audrey Talley Rostov, Napaporn Tananuvat, Chulaluck Tangmonkongvoragul, Tanya Trinh, Sonal Tuli, Phit Upaphong, Bart van Dooren, Manoj Vasudevan, Elizabeth Viriya, Maria Woodward
Journal: Ophthalmology (2021)
717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
Authors: B.I. Rini, E.R. Plimack, T.B. Powles, M.H. Voss, H.P. Gurney, R. Silverman, R. Perini, K. Rodriguez-Lopez, T.K. Choueiri
Journal: Annals of Oncology (2021)
Music as a social bond in patients with amnesia
Authors: Maria Chiara Del Mastro, Maria Rosaria Strollo, Mohamad El Haj
Journal: Behavioral and Brain Sciences (2021)

Abstract The music and social bonding (MSB) hypothesis proposes that human musicality has evolved as mechanisms supporting social bonding. We consider the MSB hypothesis under the lens of amnesia by arguing how patients with amnesia, especially those with Alzheimer's disease, can benefit from music, not only to retrieve personal memories, but also to use them for social bonding.
776P SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for pretreated advanced cervical cancer: Data from a clinical expansion cohort of a phase I study
Authors: J. Feng, J. Wang, D. Tang, Q. Zhou, J. Peng, H. Lou, Y. Sun, Y. Cai, H. Chen, X. Zhang, J. Yang, P. Liu
Journal: Annals of Oncology (2021)
591P A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Authors: R.R. Aggarwal, J. Vuky, D. VanderWeele, M. Rettig, E. Heath, M. Nasoff, A. Dorr, B. Liu, E.J. Small
Journal: Annals of Oncology (2021)